Clinical trial intelligence: the alternatives, what they cost, and what you actually need

Why is this a comparison of four different products?

Because the vendors themselves describe four different jobs.

Citeline describes Trialtrove as delivering “the insight clinical teams need to plan, benchmark, and execute trials”, “powered by more than 60,000 trusted sources” and “curated by our extensive team of therapeutically focused expert analysts”. Its sibling Pharmaprojects carries “over 90,000 drug profiles” with history “going back to 1995”. That is a curated intelligence corpus with human analysts attached, drawing on conferences, papers and press as well as registries.

Cortellis describes its Clinical Trials Intelligence as “a trusted view of the global trial landscape so teams can quickly find relevant trials, benchmark competitors, and uncover patterns to inform smarter study design and portfolio strategy”, “curated by experienced industry analysts”. Similar category: analyst-curated breadth, sold as part of a platform.

Evaluate is a different job altogether. It describes Evaluate Pharma as “the go-to source for consensus forecasts for pharma firms, investment banks, and consultancies”. If you need forecasts, consensus sales estimates or probability of success analytics, that is the category you are shopping in, and neither ComplyRx nor a registry monitor of any kind is a substitute for it.

DataLookout and ComplyRx are in a fourth category: registry change monitoring. DataLookoutdescribes itself with “Know when your competitors’ trials change” and states that “all data comes directly from ClinicalTrials.gov via their official API (v2)”. ComplyRx watches ClinicalTrials.gov for the drugs you track and reports status flips, completion date moves and enrollment changes as they are detected. Neither product employs analysts, writes forecasts, or curates beyond the registry, and any comparison that pretends otherwise is selling you something.

Who publishes a price?

Two of the five. This is the clearest structural divide in the category, and you can verify it in five minutes.

On 3 August 2026 we checked the product and pricing pages of citeline.com, clarivate.com and evaluate.com: no price, tier or figure appears on any of them. Citeline’s product pages offer a specialist conversation (“A specialist is ready to speak to you regarding your interests”); Cortellis and Evaluate work the same way. That is not a criticism. It is how enterprise intelligence is sold, and for a large organisation negotiating multi-product access it can be the right model. It does mean that if you want to know the cost today, only the two registry monitors will tell you: DataLookout’s pricing is on their homepage, and ComplyRx’s membership price is stated in its terms of service and at checkout: 31 pounds a month, or $39 for international cards, self-serve with a 7 day free trial.

Third parties do publish estimates for the enterprise platforms. We are deliberately not repeating them: the figures in circulation disagree with each other by multiples, and none is sourced to the vendors themselves.

Do the enterprise platforms alert on trial changes?

Yes, and it would be misleading to suggest otherwise. Clarivate publishes a guide to Cortellis trial alerts covering email updates “daily, weekly or monthly” including “a summary of updates in existing trials”, and Citeline’s Pharmaprojects page describes “a flexible alerting feature”. The differences are in what sits between the registry and your inbox, and in what you have to buy to get it.

The enterprise platforms are analyst-curated: their own materials describe content drawn from conferences, press and registries, checked by editorial teams. A registry monitor compares the registry record itself against yesterday’s copy and reports the difference. Both are legitimate designs. The practical questions are which fields you need watched, how directly you want to see the registry’s own words, and whether the surrounding platform is something you will use enough to justify its procurement.

What ComplyRx can state first-hand about its own alerting: it reports the change as the registry recorded it, labels estimated versus actual dates, and distinguishes a fresh change from a stale record catching up. Those distinctions come from holding the history: as of 3 August 2026, an archive of 451,414 of the 455,360 interventional studies on ClinicalTrials.gov, with a daily tier of 85,632 active trials re-checked inside 48 hours.

When are the enterprise platforms the right answer?

Genuinely often. If your questions sound like “what is the competitive landscape in this indication, including assets that have never been registered”, “which sites and investigators should we shortlist”, or “what will this market be worth in 2031”, you are buying curation, history and analysis that a registry does not contain. Citeline’s 60,000-source curation, Pharmaprojects’ history to 1995 and Evaluate’s consensus forecasts exist because registries alone cannot answer those questions. ComplyRx is not a substitute for any of that, and this page would be worthless if it pretended to be.

The honest test: list what you actually opened the platform for in the last quarter. If the answer is analyst reports, landscapes and forecasts, you are using it for what it is for. If the answer is “checking whether anything changed on the trials we compete with”, you are using an intelligence platform as a change monitor, and that is the one job you can buy separately at a published price.

When is a registry change monitor enough?

When the job is watching specific competitor programmes for movement: a status flip, a completion date that slipped, an enrollment target that changed. That job needs daily comparison against a kept history, not curation, and two self-serve products do it.

The DataLookout column is from their homepage as of 3 August 2026: they describe tracking “by sponsor or disease”, with ten fields compared daily and changes classified by severity. The structural difference is the watch unit. ComplyRx is built around the drug: you track the molecule, and every trial behind it, across every sponsor running it, comes with it, with each change labelled estimated or actual and fresh or catch-up. Which unit fits depends on whether your world is organised by company, by indication, or by asset. Ours is built for people who think in assets.

Common questions

Is there an affordable alternative to Citeline for tracking competitor trials?

It depends which part of Citeline you use. Nothing at a self-serve price replaces its analyst-curated intelligence from over 60,000 sources. If what you actually use is registry monitoring, that slice is available self-serve: ComplyRx tracks ClinicalTrials.gov changes on the drugs you follow for a flat monthly membership (currently 31 pounds, or $39 for international cards, stated in its terms of service and at checkout) with no sales call, and DataLookout monitors sponsors and diseases from $0 to $149 a month.

How much do Citeline, Cortellis and Evaluate cost?

None of the three publishes pricing. As of 3 August 2026, every route to a price on citeline.com, clarivate.com and evaluate.com is a demo request or a conversation with a specialist. Third parties publish estimates, but they conflict with each other by multiples, so treat any specific figure you read with caution.

Can I monitor clinical trials without an annual enterprise contract?

Yes. ComplyRx is self-serve with monthly billing, a price stated openly in its terms, no minimum seats and a 7 day free trial, and DataLookout is self-serve with a free tier. The enterprise platforms sell annual subscriptions through a sales process, which suits organisations buying curated intelligence rather than registry monitoring alone.